Table 1.
Pre-LATEST vs LATEST
| Pre-LATEST (n = 237) | LATEST (n = 244) |
p value | |
|---|---|---|---|
| Age (median) | 58 | 56 | 0.3816 |
| Gender (% male) | 29.5 | 34.0 | 0.3277 |
| Pre-operative fitness for surgery (%) | |||
| ASA 1 | 38.5 | 37.5 | 0.0113 |
| ASA 2 | 40.6 | 53.0 | |
| ASA 3 | 20.8 | 9.5 | |
| Medical co-morbidity (%) | |||
| Anti-platelet medication | 7.6 | 3.3 | 0.0436 |
| Ischaemic heart disease | 6.8 | 3.3 | 0.0951 |
| Hypertension | 41.2 | 26.3 | 0.0088 |
| Atrial fibrillation | 1.0 | 2.5 | 0.6779 |
| Congestive cardiac failure | 0 | 0.8 | > 0.9999 |
| Stroke/Transient ischaemic attack | 3.1 | 2.1 | 0.6927 |
| Chronic obstructive pulmonary disease | 1.0 | 3.7 | 0.2926 |
| Asthma | 6.2 | 7.0 | > 0.9999 |
| Pulmonary embolus/DVT | 0 | 1.6 | 0.5809 |
| Diabetes Mellitus | 12.4 | 9.8 | 0.5581 |
| Chronic kidney disease | 2.1 | 1.2 | 0.6254 |
| Hypothyroidism | 7.2 | 6.2 | 0.8073 |
| Clinical Presentation (%) | |||
| Dilated CBD | 3.0 | 16.4 | < 0.0001 |
| Deranged LFTs | 27.0 | 34.8 | 0.0757 |
| Hyperbilirubinaemia | 51.9 | 30.3 | < 0.0001 |
| Pancreatitis | 18.1 | 18.4 | > 0.9999 |
| Pre-operative LFTs | |||
| Bilirubin (mmol/L) | 52 | 41 | 0.0828 |
| ALP (U/L) | 387 | 227 | < 0.0001 |
| ALT (U/L) | 195 | 198 | 0.9187 |
| Pre-operative imaging | |||
| Median CBD diameter, mm (IQR) | 12 (10 – 15) | 10 (8 – 13) | < 0.0001 |
| Pre-operative ERCP (%) | |||
| Not performed | 72.2 | 87.7 | < 0.0001 |
| Diagnostic | 0.8 | 0.8 | > 0.9999 |
| False negative | 0 | 0.4 | > 0.9999 |
| Failed ERCP: failure to cannulate | 6.8 | 1.2 | 0.0019 |
| Failed ERCP: failure to extract stones | 20.3 | 9.8 | 0.0014 |
Pre-operative data. ASA American Society of Anesthesiologists; DVT deep vein thrombosis; CBD common bile duct; LFT liver function tests; ALP alkaline phosphatase; ALT alanine aminotransferase; IQR inter-quartile range; ERCP endoscopic retrograde cholangiopancreatography
Bold text denotes p < 0.05